Semaglutide and NT-proBNP in obesity-related HFpEF
Help protect your patients by reducing their risk of CKD progression 1,2 1,2 For adults with T2D, for the primary composite endpoint: Time to first occurrence of 50% sustained eGFR decline, kidney failure (sustained eGFR 100 mg/g and 300 mg/g at baseline)
EAC=external adjudication committee
2022;15:1430 Lewis AL, McEntee N, Holland J, Patel A
Additionally, tirzepatide did not attenuate the reduction of sleeping metabolic rate or 24-h sedentary energy expenditure in comparison to baseline (though not significantly different than placebo), but significantly increased fat oxidation and decreased carbohydrate and protein oxidation as compared to placebo [57]
he sees a plausible future for it in areas like addiction, where the anti-inflammatory effects may matter more than appetite suppression, while stressing it has barely been studied